Sensitization of acute lymphoblastic leukemia cells for LCL161-induced cell death by targeting redox homeostasis

Biochemical Pharmacology

Volumn 105, Issue , 2016, Pages 14-22

  Haß, Christina ^a   Belz, Katharina ^a   Schoeneberger, Hannah ^a   Fulda, Simone ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Apoptosis; IAP proteins; Leukemia; ROS; Smac

Indexed keywords

AURANOFIN; BUTHIONINE SULFOXIMINE; BUTYLATED HYDROXYANISOLE; DEXAMETHASONE; ERASTIN; N [1 CYCLOHEXYL 2 [2 [4 (4 FLUOROBENZOYL) 2 THIAZOLYL] 1 PYRROLIDINYL] 2 OXOETHYL] 2 (METHYLAMINO)PROPANAMIDE; PROTEIN INHIBITOR; REACTIVE OXYGEN METABOLITE; TROLOX C; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BUTHIONINE SULFOXIDE; METHIONINE; SULFOXIDE; THIAZOLE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CELL DEATH; CELL SURVIVAL; COLONY FORMATION; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; HOMEOSTASIS; HUMAN; HUMAN CELL; LEUKEMIA CELL; LIPID PEROXIDATION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; APOPTOSIS; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECTS; JURKAT CELL LINE; METABOLISM; OXIDATION REDUCTION REACTION; PHYSIOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DEATH; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; HOMEOSTASIS; HUMANS; JURKAT CELLS; METHIONINE; OXIDATION-REDUCTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REACTIVE OXYGEN SPECIES; SULFOXIDES; THIAZOLES;

EID: 84960435077     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2016.01.004     Document Type: Article

References (31)

1. C.H. Pui, M.V. Relling, and J.R. Downing Acute lymphoblastic leukemia N. Engl. J. Med. 350 2004 1535 1548
2. M. Stanulla, and M. Schrappe Treatment of childhood acute lymphoblastic leukemia Semin. Hematol. 46 2009 52 63
3. S. Fulda Tumor resistance to apoptosis Int. J. Cancer 124 2009 511 515
4. S. Fulda Therapeutic opportunities for counteracting apoptosis resistance in childhood leukaemia Br. J. Haematol. 145 2009 441 454
5. S. Fulda, and K.M. Debatin Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy Oncogene 25 2006 4798 4811
6. S. Fulda, and D. Vucic Targeting IAP proteins for therapeutic intervention in cancer Nat. Rev. Drug Discov. 11 2012 109 124
7. P. Hundsdoerfer, I. Dietrich, K. Schmelz, C. Eckert, and G. Henze XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL Pediatr. Blood Cancer 55 2010 260 266
8. C. Wuchter, S. Richter, D. Oltersdorf, L. Karawajew, W.D. Ludwig, and I. Tamm Differences in the expression pattern of apoptosis-related molecules between childhood and adult de novo acute myeloid leukemia Haematologica 89 2004 363 364
9. M.E. Irwin, N. Rivera-Del Valle, and J. Chandra Redox control of leukemia: From molecular mechanisms to therapeutic opportunities Antioxid. Redox Signal. 18 2013 1349 1383
10. C. Gorrini, I.S. Harris, and T.W. Mak Modulation of oxidative stress as an anticancer strategy Nat. Rev. Drug Discov. 12 2013 931 947
11. M. Repetto, J. Semprine, and A. Boveris Chemical mechanism, biological implications and analytical determination A. Catala, Lipid Peroxidation 2012 InTech, Europe Rijeka, Croatia 2013 2030
12. W.S. Yang, and B.R. Stockwell Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells Chem. Biol. 15 2008 234 245
13. D. Trachootham, J. Alexandre, and P. Huang Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nat. Rev. Drug Discov. 8 2009 579 591
14. L. Zawel, C. Straub, B. Firestone, J. Sullivan, K. Levine, D. Porter, and et al. Therapeutic targeting of inhibitor of apoptosis proteins Proceedings of the 101st Annual Meeting of the American Association for Cancer Research 2010 April 17-21, Washington, DC, AACR, Philadelphia, PA Cancer Res. 70 78 Suppl. 2010 (abstract nr 138)
15. B. Firestone, C. Conway, G. Yang, H. Gao, D. Porter, J. Slisz, and et al. Correlation between TNFα and LCL161 anti-tumor activity in patient derived xenograft models of human cancer Mol. Cancer Ther. 8 12 Suppl. 2009 B27
16. J.R. Infante, E.C. Dees, A.J. Olszanski, S.V. Dhuria, S. Sen, S. Cameron, and et al. Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors J. Clin. Oncol. 32 2014 3103 3110
17. M. Fakler, S. Loeder, M. Vogler, K. Schneider, I. Jeremias, K.M. Debatin, and et al. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance Blood 113 2009 1710 1722
18. S. Fulda, G. Strauss, E. Meyer, and K.M. Debatin Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells Blood 95 2000 301 308
19. K. Belz, H. Schoeneberger, S. Wehner, A. Weigert, H. Bonig, T. Klingebiel, and et al. Smac mimetic and glucocorticoids synergize to induce apoptosis in childhood ALL by promoting ripoptosome assembly Blood 124 2014 240 250
20. H. Schoeneberger, K. Belz, B. Schenk, and S. Fulda Impairment of antioxidant defense via glutathione depletion sensitizes acute lymphoblastic leukemia cells for Smac mimetic-induced cell death Oncogene 34 2015 4032 4043
21. A. Gomes, E. Fernandes, and J.L. Lima Fluorescence probes used for detection of reactive oxygen species J. Biochem. Biophys. Methods 65 2005 45 80
22. S.J. Dixon, K.M. Lemberg, M.R. Lamprecht, R. Skouta, E.M. Zaitsev, C.E. Gleason, and et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death Cell 149 2012 1060 1072
23. O.W. Griffith Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis J. Biol. Chem. 257 1982 13704 13712
24. B. Halliwell, and J.M. Gutteridge Oxygen toxicity, oxygen radicals, transition metals and disease Biochem. J. 219 1984 1 14
25. E. Varfolomeev, J.W. Blankenship, S.M. Wayson, A.V. Fedorova, N. Kayagaki, P. Garg, and et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis Cell 131 2007 669 681
26. S. Fulda Molecular pathways: Targeting inhibitor of apoptosis proteins in cancer - from molecular mechanism to therapeutic application Clin. Cancer Res. 20 2014 289 295
27. P.R. Kearns, R. Pieters, M.M. Rottier, A.D. Pearson, and A.G. Hall Raised blast glutathione levels are associated with an increased risk of relapse in childhood acute lymphocytic leukemia Blood 97 2001 393 398
28. Z.T. Maung, L. Hogarth, M.M. Reid, S.J. Proctor, P.J. Hamilton, and A.G. Hall Raised intracellular glutathione levels correlate with in vitro resistance to cytotoxic drugs in leukaemic cells from patients with acute lymphoblastic leukemia Leukemia 8 1994 1487 1491
29. S. Fulda Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: Molecular mechanisms and therapeutic opportunities Leukemia 28 2014 1414 1422
30. S. Loeder, M. Fakler, H. Schoeneberger, S. Cristofanon, J. Leibacher, N. Vanlangenakker, and et al. RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis Leukemia 26 2012 1020 1029
31. S. Loeder, A. Drensek, I. Jeremias, K.M. Debatin, and S. Fulda Small molecule XIAP inhibitors sensitize childhood acute leukemia cells for CD95-induced apoptosis Int. J. Cancer 126 2010 2216 2228